Evogene Ltd.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 0.3
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 18, 2026 | Before market open | $300.00K | $-0.14 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 5, 2026 | Before market open | $300.00K | $-0.61 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 19, 2025 | Before market open | $900.00K | $-0.50 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 6, 2025 | Before market open | $1.60M | $0.06 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 22, 2024 | Before market open | $914.00K | $-1.06 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 7, 2024 | Before market open | $578.00K | $-0.13 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 8, 2023 | Before market open | – | – | – |
Company guidance
Outlook given with results on Aug 18, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| cash usage | full-year 2026 | $8.50M to $9.50M | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements Evogene filed with the SEC
13 Gad Feinstein Street, Park Rehovot, Rehovot
EX-99.1 to Form 6-K
13 Gad Feinstein St., Park Rehovot
EX-99.2 to Form 6-K
PROXY FOR SPECIAL GENERAL MEETING OF SHAREHOLDERS
EX-99.3 to Form 6-K
Financial Review and Prospects - Six Months Ended June 30, 2026
EX-99.2 to Form 6-K
o o o o o o o o
EX-99.1 to Form 6-K
Second Quarter and First Half 2026 Financial Results
EX-99.1 to Form 6-K
August 18 , 2026 EARNINGS CALL Q 2 2026
EX-99.2 to Form 6-K
13 Gad Feinstein Street, Park Rehovot, Rehovot 7638517, Israel
EX-99.1 to Form 6-K
13 Gad Feinstein St., Park Rehovot
EX-99.2 to Form 6-K
PROXY FOR THE 2026 ANNUAL GENERAL MEETING OF SHAREHOLDERS
EX-99.3 to Form 6-K
First Quarter 2026 Financial Results
EX-99.1 to Form 6-K
˥ May 20 , 2026 EARNINGS CALL Q 1 2026 OFER HAVIV | PRESIDENT & CEO
EX-99.2 to Form 6-K
Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification
EX-99.1 to Form 6-K
Evogene Reports Fourth Quarter and Full Year 2025 Financial Results
EX-99.1 to Form 6-K
March 05, 2026 EARNINGS CALL Q4 & ANNUAL 2025 OFER HAVIV | PRESIDENT &
EX-99.2 to Form 6-K
Evogene Releases CEO Letter to Shareholders
EX-99.1 to Form 6-K
Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce
EX-99.1 to Form 6-K
Evogene Announces Appointment of Dr. Olga Nissan
EX-99.1 to Form 6-K
Evogene Reports Third Quarter 2025 Financial Results
EX-99.1 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
Operating and Financial Review and Prospects
EX-99.2 to Form 6-K
Sep 10,2025 ev°gene Al-first discovery platform generating
EX-99.1 to Form 6-K
Evogene Reports Second Quarter 2025 Financial Results
EX-99.1 to Form 6-K
Q2 2025 EARNINGS CALL OFER HAVIV | PRESIDENT & CEO August 19, 2025
EX-99.2 to Form 6-K
PROXY FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS
EX-99.1 to Form 6-K
Evogene Announces Completion of Transaction for the Sale of
EX-99.1 to Form 6-K
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS
EX-99.1 to Form 6-K
2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS
EX-99.2 to Form 6-K
PROXY FOR THE ANNUAL GENERAL MEETING OF SHAREHOLDERS
EX-99.3 to Form 6-K
Evogene Reports First Quarter 2025 Financial Results
EX-99.1 to Form 6-K
Q1 2025 EARNINGS CALL OFER HAVIV | PRESIDENT & CEO May 21, 2025
EX-99.2 to Form 6-K
ICL to Acquire the Activity of Evogene’s Subsidiary , Lavie Bio
EX-99.1 to Form 6-K
Evogene Reports Fourth Quarter and Full Year 2024 Financial Results
EX-99.1 to Form 6-K
Q4 2024 EARNINGS CALL OFER HAVIV | PRESIDENT & CEO March 06, 2025
EX-99.2 to Form 6-K
Evogene Announces the Appointment of Nir Nimrodi as the New
EX-99.1 to Form 6-K